Adcytherix
Founded 2022 · 3 employees on LinkedIn · 8 known investors
Find your way into Adcytherix
48 people in our graph share verified history with the Adcytherix team — schools, employers, funds. One of them is your warm intro.
Dominik Escherunlockedknows Xavier Preville · together at Adcytherix (overlapped)
×4knows the team · via INSERM
×6knows the team · via Université Claude Bernard Lyon 1
knows the team · via Transgene
Adcytherix is a clinical-stage biopharmaceutical company developing next-generation antibody-drug conjugates (ADCs) that use approved cancer drugs as payloads combined with optimized conjugation design to overcome resistance in precision oncology. Its lead candidate, ADCX-020, is being evaluated in a Phase 1 study in patients with advanced solid tumors.
Founders & leadership
Adcytherix was founded in 2022 by Jack Elands and Xavier Preville.
JE
Jack ElandsinFounder & CEO
XP
Xavier PrevilleinCo-founder, VP & Head of Research & Preclinical DevelopmentXavier Preville is co-founder, VP, and Head of Research & Preclinical Development at Adcytherix, a clinical-stage biopharmaceutical company developing antibody-drug conjugates for precision oncology. He has over 20 years of biotech experience as a preclinical group and department head specializing in onco-immunology, with expertise in translational medicine, biomarker assay development and validation in GLP settings, and managing external collaborations with CMOs, CROs, and academic teams.
JH
Jan H.M. SchellensinChief Medical Officer
TM
Thierry MenguyinVP & Head of CMC Operations
JA
Jaime ArangoinChief Financial Officer
PJ
Paul JacksoninChief Operating Officer
MG
Magali GibouinChief Regulatory & Quality Officer
IP
Inka PawlitzkyinVP & Head of Clinical Development
JG
Julia GavrilyukinVP & Head of ADC Technology Development
Investors · 8
Funding
SEC filings, press & company announcements- Undisclosed amountSeries AOct 2025 · 2 sourcesSource ↗
- Undisclosed amountseed fundingJun 2024 · 2 sourcesSource ↗
Source: company announcements and press reports — follow each round's link for the claim.
In the news
Frequently asked questions
- What does Adcytherix do?
- Adcytherix is a clinical-stage biopharmaceutical company developing next-generation antibody-drug conjugates (ADCs) that use approved cancer drugs as payloads combined with optimized conjugation design to overcome resistance in precision oncology. Its lead candidate, ADCX-020, is being evaluated in a Phase 1 study in patients with advanced solid tumors.
- Who founded Adcytherix?
- Adcytherix was founded by Jack Elands, Xavier Preville in 2022.
- Who are Adcytherix's investors?
- Adcytherix's investors include aMoon, RA Capital, Bpifrance, Andera Partners, Angelini Ventures, Kurma Partners, Pontifax Venture Capital, Pureos Bioventures.